

# William F Young

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/230150/publications.pdf>

Version: 2024-02-01

110  
papers

13,755  
citations

61984

43  
h-index

24258

110  
g-index

114  
all docs

114  
docs citations

114  
times ranked

6754  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical, imaging and biochemical presentation of cystic pheochromocytomas. <i>Clinical Endocrinology</i> , 2023, 98, 32-40.	2.4	5
2	Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors. <i>Annals of Internal Medicine</i> , 2022, 175, 325-334.	3.9	53
3	Histopathology and Genetic Causes of Primary Aldosteronism in Young Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 2473-2482.	3.6	4
4	Maternal and fetal outcomes in pheochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 13-21.	11.4	37
5	Differences in outcomes of bilateral adrenalectomy in patients with ectopic ACTH producing tumor of known and unknown origin. <i>American Journal of Surgery</i> , 2021, 221, 460-464.	1.8	6
6	Biological Effective Dose as a Predictor of Hypopituitarism After Single-Fraction Pituitary Adenoma Radiosurgery: Dosimetric Analysis and Cohort Study of Patients Treated Using Contemporary Techniques. <i>Neurosurgery</i> , 2021, 88, E330-E335.	1.1	10
7	The Role for Metyrosine in the Treatment of Patients With Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2393-e2401.	3.6	19
8	Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications. <i>Mayo Clinic Proceedings</i> , 2021, 96, 788-814.	3.0	45
9	Presentation and outcomes of adrenal ganglioneuromas: A cohort study and a systematic review of literature. <i>Clinical Endocrinology</i> , 2021, 95, 47-57.	2.4	13
10	Collision of Craniopharyngioma and Pituitary Adenoma: Comprehensive Review of an Extremely Rare Sellar Condition. <i>World Neurosurgery</i> , 2021, 149, e51-e62.	1.3	8
11	Pheochromocytoma and Paraganglioma in Pregnancy: a New Era. <i>Current Cardiology Reports</i> , 2021, 23, 60.	2.9	13
12	International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. <i>Nature Reviews Endocrinology</i> , 2021, 17, 435-444.	9.6	80
13	Concomitant Pheochromocytoma and Primary Aldosteronism: A Case Series and Literature Review. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab107.	0.2	11
14	Multiple endocrine neoplasia type 1 in children and adolescents: Clinical features and treatment outcomes. <i>Surgery</i> , 2021, , .	1.9	10
15	Diagnostic Accuracy of Dehydroepiandrosterone Sulfate and Corticotropin in Autonomous Cortisol Secretion. <i>Biomedicines</i> , 2021, 9, 741.	3.2	8
16	Cardiometabolic Outcomes and Mortality in Patients with Adrenal Adenomas in a Population-based Setting. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 3320-3330.	3.6	13
17	Radiosurgical Management of Patients With Persistent or Recurrent Cushing Disease After Prior Transsphenoidal Surgery: A Management Algorithm Based on a 25-Year Experience. <i>Neurosurgery</i> , 2020, 86, 557-564.	1.1	15
18	Comparison between functional and non-functional adrenocortical carcinoma. <i>Surgery</i> , 2020, 167, 216-223.	1.9	18

#	ARTICLE	IF	CITATIONS
19	Response to Letter to the Editor: “Pheochromocytoma Characteristics and Behavior Differ Depending on Method of Discovery” Journal of Clinical Endocrinology and Metabolism, 2020, 105, 569-570.	3.6	0
20	Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort study. Lancet Diabetes and Endocrinology, the, 2020, 8, 894-902.	11.4	140
21	Response to Letter to the Editor: “CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma” Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3842-e3843.	3.6	0
22	Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes and Endocrinology, the, 2020, 8, 773-781.	11.4	129
23	Not all adrenal incidentalomas require biochemical testing to exclude pheochromocytoma: Mayo clinic experience and a meta- analysis. Gland Surgery, 2020, 9, 362-371.	1.1	18
24	Bilateral Adrenalectomy: Differences between Cushing Disease and Ectopic ACTH-Producing Tumors. Annals of Surgical Oncology, 2020, 27, 3851-3857.	1.5	4
25	Bilateral pheochromocytoma: Clinical characteristics, treatment and longitudinal follow-up. Clinical Endocrinology, 2020, 93, 288-295.	2.4	18
26	Metastatic Pheochromocytoma: In Search of a Cure. Endocrinology, 2020, 161, .	2.8	10
27	The Impact of Mild Autonomous Cortisol Secretion on Bone Turnover Markers. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1469-1477.	3.6	15
28	Tumor-specific prognosis of mutation-positive patients with head and neck paragangliomas. Journal of Vascular Surgery, 2020, 71, 1602-1612.e2.	1.1	16
29	The Impact of Insulin-Like Growth Factor Index and Biologically Effective Dose on Outcomes After Stereotactic Radiosurgery for Acromegaly: Cohort Study. Neurosurgery, 2020, 87, 538-546.	1.1	31
30	Clinical course of adrenal myelolipoma: A long-term longitudinal follow-up study. Clinical Endocrinology, 2020, 93, 11-18.	2.4	39
31	Pheochromocytoma and Paraganglioma. New England Journal of Medicine, 2019, 381, 552-565.	27.0	437
32	Synonymous but Not Silent: A Synonymous VHL Variant in Exon 2 Confers Susceptibility to Familial Pheochromocytoma and von Hippel-Lindau Disease. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3826-3834.	3.6	17
33	Primary Aldosteronism: Does Underlying Pathology Impact Clinical Presentation and Outcomes Following Unilateral Adrenalectomy?. World Journal of Surgery, 2019, 43, 2469-2476.	1.6	11
34	Pheochromocytoma Characteristics and Behavior Differ Depending on Method of Discovery. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1386-1393.	3.6	106
35	Impact of 123I-MIBG Scintigraphy on Clinical Decision-Making in Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3812-3820.	3.6	19
36	Efficacy and Safety of Ablative Therapy in the Treatment of Patients with Metastatic Pheochromocytoma and Paraganglioma. Cancers, 2019, 11, 195.	3.7	45

#	ARTICLE	IF	CITATIONS
37	CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 312-318.	3.6	96
38	Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. Journal of Internal Medicine, 2019, 285, 126-148.	6.0	184
39	Cushing syndrome: uncovering Carney complex due to novel PRKAR1A mutation. Endocrinology, Diabetes and Metabolism Case Reports, 2019, 2019, .	0.5	3
40	When Biochemical Phenotype Predicts Genotype: Pheochromocytoma and Paraganglioma. American Journal of Medicine, 2018, 131, 506-509.	1.5	9
41	Clinical, Biochemical, and Radiological Characteristics of a Single-Center Retrospective Cohort of 705 Large Adrenal Tumors. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2018, 2, 30-39.	2.4	70
42	External beam radiation therapy for advanced/unresectable malignant paraganglioma and pheochromocytoma. Advances in Radiation Oncology, 2018, 3, 25-29.	1.2	47
43	Hypopituitarism After Single-Fraction Pituitary Adenoma Radiosurgery: Dosimetric Analysis Based on Patients Treated Using Contemporary Techniques. International Journal of Radiation Oncology Biology Physics, 2018, 101, 618-623.	0.8	20
44	Primary aldosteronism: making sense of partial data sets from failed adrenal venous sampling-suppression of adrenal aldosterone production can be used in clinical decision making. Surgery, 2018, 163, 801-806.	1.9	38
45	Impact of hypercortisolism on skeletal muscle mass and adipose tissue mass in patients with adrenal adenomas. Clinical Endocrinology, 2018, 88, 209-216.	2.4	44
46	Contralateral suppression of aldosterone at adrenal venous sampling predicts hyperkalemia following adrenalectomy for primary aldosteronism. Surgery, 2018, 163, 183-190.	1.9	33
47	Diagnostic performance of unenhanced computed tomography and <sup>18</sup> F-fluorodeoxyglucose positron emission tomography in indeterminate adrenal tumours. Clinical Endocrinology, 2018, 88, 30-36.	2.4	41
48	Hemodynamic instability during percutaneous ablation of extra-adrenal metastases of pheochromocytoma and paragangliomas: a case series. BMC Anesthesiology, 2018, 18, 158.	1.8	10
49	Diagnostic Testing for Elevated Cortisol in the Setting of an Adrenal Mass. JAMA - Journal of the American Medical Association, 2018, 320, 1373.	7.4	1
50	Primary adrenal insufficiency due to bilateral infiltrative disease. Endocrine, 2018, 62, 721-728.	2.3	34
51	Resection of Intrathoracic Paraganglioma With and Without Cardiopulmonary Bypass. Annals of Thoracic Surgery, 2018, 105, 1160-1167.	1.3	8
52	65 YEARS OF THE DOUBLE HELIX: Genetics informs precision practice in the diagnosis and management of pheochromocytoma. Endocrine-Related Cancer, 2018, 25, T201-T219.	3.1	52
53	Extensive clinical experience: Hypothalamic-pituitary-adrenal axis recovery after adrenalectomy for corticotropin-independent cortisol excess. Clinical Endocrinology, 2018, 89, 721-733.	2.4	43
54	Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors. Endocrine-Related Cancer, 2018, 25, 783-793.	3.1	42

#	ARTICLE	IF	CITATIONS
55	Surgical Treatment of Malignant Pheochromocytoma and Paraganglioma: Retrospective Case Series. <i>Annals of Surgical Oncology</i> , 2017, 24, 1546-1550.	1.5	38
56	Assessing for Multiple Endocrine Neoplasia Type 1 in Patients Evaluated for Zollinger-Ellison Syndrome—Clues to a Safer Diagnostic Process. <i>American Journal of Medicine</i> , 2017, 130, 603-605.	1.5	14
57	Characterizing and predicting the Nelson-Salassa syndrome. <i>Journal of Neurosurgery</i> , 2017, 127, 1277-1287.	1.6	24
58	Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 689-699.	11.4	595
59	Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3296-3305.	3.6	220
60	Perioperative hemodynamics and outcomes of patients on metyrosine undergoing resection of pheochromocytoma or paraganglioma. <i>International Journal of Surgery</i> , 2017, 46, 1-6.	2.7	20
61	Perioperative outcomes of syndromic paraganglioma and pheochromocytoma resection in patients with von Hippel-Lindau disease, multiple endocrine neoplasia type 2, or neurofibromatosis type 1. <i>Surgery</i> , 2017, 162, 1259-1269.	1.9	20
62	Clinical features and prognosis of thymic neuroendocrine tumours associated with multiple endocrine neoplasia type 1: A single-centre study, systematic review and meta-analysis. <i>Clinical Endocrinology</i> , 2017, 87, 706-716.	2.4	27
63	Outcomes of patients with metastatic pheochromocytoma and paraganglioma: A systematic review and meta-analysis. <i>Clinical Endocrinology</i> , 2017, 87, 440-450.	2.4	76
64	Pheochromocytoma with Synchronous Ipsilateral Adrenal Cortical Adenoma. <i>World Journal of Surgery</i> , 2017, 41, 3147-3153.	1.6	6
65	High-Resolution, Accurate-Mass (HRAM) Mass Spectrometry Urine Steroid Profiling in the Diagnosis of Adrenal Disorders. <i>Clinical Chemistry</i> , 2017, 63, 1824-1835.	3.2	76
66	Preoperative Levels of Catecholamines and Metanephrines and Intraoperative Hemodynamics of Patients Undergoing Pheochromocytoma and Paraganglioma Resection. <i>Urology</i> , 2017, 100, 131-138.	1.0	48
67	Pheochromocytoma and paraganglioma in patients with neurofibromatosis type 1. <i>Clinical Endocrinology</i> , 2017, 86, 141-149.	2.4	83
68	When and how should patients with multiple endocrine neoplasia type 1 be screened for thymic and bronchial carcinoid tumours?. <i>Clinical Endocrinology</i> , 2016, 84, 13-16.	2.4	12
69	Procedural and clinical outcomes of percutaneous adrenal biopsy in a high-risk population for adrenal malignancy. <i>Clinical Endocrinology</i> , 2016, 85, 710-716.	2.4	31
70	Prevalence of parathyroid carcinoma in 348 patients with multiple endocrine neoplasia type 1 — case report and review of the literature. <i>Clinical Endocrinology</i> , 2016, 84, 244-249.	2.4	44
71	A Novel CYP11B2-Specific Imaging Agent for Detection of Unilateral Subtypes of Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1008-1015.	3.6	58
72	The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1889-1916.	3.6	1,921

#	ARTICLE	IF	CITATIONS
73	15 YEARS OF PARAGANGLIOMA: Metabolism and pheochromocytoma/paraganglioma. Endocrine-Related Cancer, 2015, 22, T83-T90.	3.1	9
74	Is the endocrine research pipeline broken? A systematic evaluation of the Endocrine Society clinical practice guidelines and trial registration. BMC Medicine, 2015, 13, 187.	5.5	19
75	Thymic and Bronchial Carcinoid Tumors in Multiple Endocrine Neoplasia Type 1: The Mayo Clinic Experience from 1977 to 2013. Hormones and Cancer, 2015, 6, 247-253.	4.9	36
76	A Coaxial Guide Wireâ€“Catheter Technique to Facilitate Right Adrenal Vein Sampling: Evaluation in 76 Patients. Journal of Vascular and Interventional Radiology, 2015, 26, 1871-1873.	0.5	6
77	An Expert Consensus Statement on Use of Adrenal Vein Sampling for the Subtyping of Primary Aldosteronism. Hypertension, 2014, 63, 151-160.	2.7	475
78	Metastasectomy of neuroendocrine tumors in patients with multiple endocrine neoplasia type 1. American Journal of Surgery, 2014, 208, 1047-1053.	1.8	5
79	Accuracy of Adrenal Imaging and Adrenal Venous Sampling in Predicting Surgical Cure of Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2712-2719.	3.6	169
80	A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. Journal of Hypertension, 2011, 29, 980-990.	0.5	214
81	Conventional Imaging in Adrenocortical Carcinoma: Update and Perspectives. Hormones and Cancer, 2011, 2, 341-347.	4.9	44
82	Endocrine Hypertension: Then and Now. Endocrine Practice, 2010, 16, 888-902.	2.1	25
83	What are the keys to successful adrenal venous sampling (AVS) in patients with primary aldosteronism?. Clinical Endocrinology, 2009, 70, 14-17.	2.4	193
84	The Clinical Conundrum of Corticotropinâ€“Independent Autonomous Cortisol Secretion in Patients with Bilateral Adrenal Masses. World Journal of Surgery, 2008, 32, 856-862.	1.6	92
85	Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3266-3281.	3.6	1,440
86	The Incidentally Discovered Adrenal Mass. New England Journal of Medicine, 2007, 356, 601-610.	27.0	975
87	Role for laparoscopic adrenalectomy in patients with Cushing's syndrome. Arquivos Brasileiros De Endocrinologia E Metabologia, 2007, 51, 1349-1354.	1.3	10
88	Primary aldosteronism: renaissance of a syndrome. Clinical Endocrinology, 2007, 66, 607-618.	2.4	574
89	The diagnostic efficacy of urinary fractionated metanephrines measured by tandem mass spectrometry in detection of pheochromocytoma. Clinical Endocrinology, 2007, 66, 703-708.	2.4	98
90	Adrenal causes of hypertension: Pheochromocytoma and primary aldosteronism. Reviews in Endocrine and Metabolic Disorders, 2007, 8, 309-320.	5.7	84

#	ARTICLE	IF	CITATIONS
91	Paragangliomas: Clinical Overview. Annals of the New York Academy of Sciences, 2006, 1073, 21-29.	3.8	178
92	Re: "Selective Use of Adrenal Venous Sampling in the Lateralization of Aldosterone-Producing Adenomas. World Journal of Surgery, 2006, 30, 886-887.	1.6	12
93	Laparoscopic Adrenalectomy for Patients Who Have Cushing's Syndrome. Endocrinology and Metabolism Clinics of North America, 2005, 34, 489-499.	3.2	23
94	Role for adrenal venous sampling in primary aldosteronism. Surgery, 2004, 136, 1227-1235.	1.9	644
95	Increased Diagnosis of Primary Aldosteronism, Including Surgically Correctable Forms, in Centers from Five Continents. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1045-1050.	3.6	862
96	Primary aldosteronism " treatment options. Growth Hormone and IGF Research, 2003, 13, S102-S108.	1.1	26
97	Minireview: Primary Aldosteronism"Changing Concepts in Diagnosis and Treatment. Endocrinology, 2003, 144, 2208-2213.	2.8	343
98	Aldosterone-secreting adrenocortical carcinomas are associated with unique operative risks and outcomes. Surgery, 2002, 132, 1008-1012.	1.9	33
99	Pituitary Adenoma in Carney Complex: An Immunohistochemical, Ultrastructural, and Immunoelectron Microscopic Study. Ultrastructural Pathology, 2002, 26, 345-353.	0.9	36
100	Primary Aldosteronism. Annals of the New York Academy of Sciences, 2002, 970, 61-76.	3.8	76
101	A review of the medical treatment of primary aldosteronism. Journal of Hypertension, 2001, 19, 353-361.	0.5	166
102	Primary Aldosteronism: Factors Associated with Normalization of Blood Pressure after Surgery. Annals of Internal Medicine, 2001, 135, 258.	3.9	289
103	Cushing syndrome due to ectopic adrenocorticotrophic hormone secretion. World Journal of Surgery, 2001, 25, 934-940.	1.6	226
104	Clinically Silent Corticotroph Tumors of the Pituitary Gland. Neurosurgery, 2000, 47, 723-730.	1.1	160
105	Prevalence of Primary Aldosteronism among Asian Hypertensive Patients in Singapore1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2854-2859.	3.6	300
106	Distribution and regulation of proconvertases PC1 and PC2 in human pituitary adenomas. Pituitary, 1999, 1, 187-195.	2.9	23
107	Laparoscopic versus Open Posterior Adrenalectomy: Comparison of Acute-phase Response and Wound Healing in the Cushingoid Porcine Model. World Journal of Surgery, 1998, 22, 613-620.	1.6	21
108	Renin-Independent hypermineralocorticoidism. Trends in Endocrinology and Metabolism, 1994, 5, 97-106.	7.1	39

#	ARTICLE	IF	CITATIONS
109	Association of Hypokalemia, Aldosteronism, and Renal Cysts. New England Journal of Medicine, 1990, 322, 345-351.	27.0	153
110	Erythrocyte Catechol-O-Methyltransferase, Platelet Monoamine Oxidase, and Platelet Phenol Sulfotransferase Activities in Patients with Prolactin Secreting Pituitary Adenomas*. Journal of Clinical Endocrinology and Metabolism, 1984, 59, 1207-1210.	3.6	3